C4 Therapeutics Inc (NASDAQ:CCCC) shares, rose in value, with the stock price down by -2.28% to the previous day’s close as strong demand from buyers drove the stock to $7.72.
Actively observing the price movement in the last trading, the stock closed the session at $7.90. The value of beta (5-year monthly) was 3.25. Referring to stock’s 52-week performance, its high was $11.88, and the low was $1.06. On the whole, CCCC has fluctuated by -26.48% over the past month.
With the market capitalization of C4 Therapeutics Inc currently standing at about $529.59 million, investors are eagerly awaiting this quarter’s results, scheduled for May 02, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.35, which is expected to increase to -$0.28 for fiscal year -$1.85 and then to about -$1.92 by fiscal year 2025. Data indicates that the EPS growth is expected to be 30.20% in 2025, while the next year’s EPS growth is forecast to be -3.80%.
According to the average forecast, sales growth in current quarter could jump up 57.30%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $26.83 million, representing an increase of 29.30% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CCCC’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CCCC currently trading nearly -15.09% and -4.58% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.24, while the 7-day volatility ratio is showing 5.18% which for the 30-day chart, stands at 7.28%. Furthermore, C4 Therapeutics Inc (CCCC)’s beta value is 3.19, and its average true range (ATR) is 0.64.
A comparison of C4 Therapeutics Inc (CCCC) with its peers suggests the former has fared considerably weaker in the market. CCCC showed an intraday change of -2.28% in last session, and over the past year, it grew by 141.25%%.
Data on historical trading for C4 Therapeutics Inc (NASDAQ:CCCC) indicates that the trading volumes over the past 10 days have averaged 1.46 million and over the past 3 months, they’ve averaged 3.96 million. According to company’s latest data on outstanding shares, there are 60.47 million shares outstanding.
Nearly 15.85% of C4 Therapeutics Inc’s shares belong to company insiders and institutional investors own 63.54% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.29 million shares as on Mar 15, 2024, resulting in a short ratio of 1.43. According to the data, the short interest in C4 Therapeutics Inc (CCCC) stood at 7.71% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 3.18 million. The stock has risen by 36.64% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CCCC stock heading into the next quarter.
